PhenMap predicts bevacizumab response in bowel cancer
SkimNews Take
Deploying AI to shrink rather than expand the eligible patient pool signals a triage logic that could reshape how approved drugs are deployed across cost-constrained health systems.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- PhenMap integrated complex tumour genetic data to identify response patterns to bevacizumab in advanced bowel cancer patients.
- Institute of Cancer Research partnered with RCSI University of Medicine and Health Sciences to develop the AI method, tracking 117 European patients treated with chemotherapy and bevacizumab.
- Bevacizumab, approved by the NHS in December, is effective for only a small subset of advanced bowel cancer patients and can cause serious side effects such as blood clots and gastrointestinal issues.
- Anguraj Sadanandam said the AI tool can pinpoint patients least likely to benefit from bevacizumab, potentially sparing thousands in England from unnecessary side effects.
Why it matters: Patients with advanced bowel cancer gain a potential diagnostic test that could spare thousands from receiving bevacizumab’s serious side effects, while the NHS could reduce costly ineffective drug use; clinicians would have data‑driven guidance, but the tool still requires larger‑scale validation.
